Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LHZWB
ADC Name	ASN004
Synonyms	ASN004 Click to Show/Hide
Organization	Asana BioSciences (Originator);Mersana Therapeutics
Drug Status	Phase 1 (discontinued)
Drug-to-Antibody Ratio	10~15
Structure
		2D MOL
Antibody Name	Anti-5T4 scFv-Fc mAb		Antibody Info
Antigen Name	Trophoblast glycoprotein (TPBG)		Antigen Info
Payload Name	AF-HPA		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Fleximer polymer		Linker Info
Conjugate Type	Random Cysteines

The indication landscape of This ADC(2027 Update)

The clinical trial pipeline of This ADC(2027 Update)

Indication

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

New Drug Application

Approved

Breast cancer

1 Trials

Trial ID
NCT04410224

Colorectal cancer

1 Trials

Trial ID
NCT04410224

Kidney cancer

1 Trials

Trial ID
NCT04410224

Liver cancer

1 Trials

Trial ID
NCT04410224

Lung cancer

1 Trials

Trial ID
NCT04410224

Ovarian cancer

1 Trials

Trial ID
NCT04410224

Unspecific solid tumor

1 Trials

Trial ID
NCT04410224

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT04410224	PHASE1	An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors Click to Show/Hide

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 17 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 28.2	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 54.3	%	Lung cancer cells	Lung cancer
Tumor Growth Inhibition value (TGI)	≈ 55.5	%	Cervical advanced-stage cancer cells	Cervical advanced-stage cancer
Tumor Growth Inhibition value (TGI)	≈ 94.2	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 96.3	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	Lung cancer cells	Lung cancer
Tumor Growth Inhibition value (TGI)	≈ 100	%	Lung cancer cells	Lung cancer
Tumor Growth Inhibition value (TGI)	≈ 100	%	Gastric cancer cells	Gastric cancer
Tumor Growth Inhibition value (TGI)	≈ 100	%	Gastric cancer cells	Gastric cancer
Tumor Growth Inhibition value (TGI)	≈ 100	%	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	A431 cells	Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	A431 cells	Skin squamous cell carcinoma

Revealed Based on the Cell Line Data

Click To Hide/Show 32 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.07	nM	SK-BR-3 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.09	nM	SCaBER cells	Bladder squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.09	nM	MDA-MB-231 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.12	nM	A-375 cells	Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50)	0.12	nM	5637 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.15	nM	MCF-7 cells	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.17	nM	DU145 cells	Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.18	nM	HeLa cells	Endocervical adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.23	nM	MDA-MB-231 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.25	nM	A-549 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.26	nM	A431 cells	Skin squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.31	nM	SW780 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.34	nM	U-87MG cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	0.42	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.42	nM	PC-3 cells	Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.44	nM	JEG-3 cells	Gestational choriocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.56	nM	MDA-MB-468 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.57	nM	HT29 cells	Colon cancer
Half Maximal Inhibitory Concentration (IC50)	0.62	nM	NCI-N87 cells	Gastric tubular adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.66	nM	TCCSUP cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.76	nM	HT-1197 cells	Recurrent bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.78	nM	RT-4 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.93	nM	T24 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.95	nM	NCI-H1975 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	1.03	nM	HCC1937 cells	Breast ductal carcinoma
Half Maximal Inhibitory Concentration (IC50)	1.05	nM	NCI-H1299 cells	Lung large cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	1.06	nM	HT-1376 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	1.34	nM	DMS 114 cells	Lung small cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	1.53	nM	UM-UC-3 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	4.28	nM	J82 cells	Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50)	9.01	nM	Hep-G2 cells	Hepatoblastoma
Half Maximal Inhibitory Concentration (IC50)	9.03	nM	LNCaP cells	Prostate carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligible patients must have histologically confirmed advanced solid tumors (dose expansion limited to 5T4-expressing cancers like colorectal, breast, and ovarian) with progression after standard therapy or no standard options. Key exclusions include untreated brain metastases (>1 cm or symptomatic), LVEF <50%, and hematologic malignancies. All patients require measurable disease (exceptions per Medical Monitor), ECOG 0-1, adequate organ function, and compliance with contraception (3 months post-treatment). Archival/fresh tumor tissue (mandatory for 5T4 confirmation in some cohorts) must be provided. Click to Show/Hide
Administration Dosage	Patients will receive escalating doses of ASN004 to identify the best dose for further study.
*Related Clinical Trial*
NCT Number	NCT04410224	Clinical Status	PHASE1
Clinical Description	An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Primary Endpoint	The study will determine the Maximum Tolerated Dose (MTD) of ASN004 by assessing treatment-related adverse events (AEs) and dose-limiting toxicities (DLTs) within the first 21 days (for Q3W dosing) or 28 days (for Q4W dosing) of treatment. The MTD will define the highest dose with acceptable safety for future studies.
Other Endpoint	Pharmacokinetic (PK) parameters will be evaluated over the first 63 days, including plasma concentration (AUC), maximum steady-state concentration (Cmax), and terminal elimination rate. Tumor response will be tracked for one year using RECIST v1.1 criteria, measuring changes in lesion size, resolution of non-measurable lesions, and appearance of new lesions. Click to Show/Hide

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 17 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28.20%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 0.3 mg/kg single dose. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.30%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 0.3 mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung cancer	Lung cancer cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.50%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 1 mg/kg Q4D 4.
In Vivo Model	Cervical advanced-stage cancer CDX model
In Vitro Model	Cervical advanced-stage cancer	Cervical advanced-stage cancer cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.20%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 1 mg/kg single dose. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.30%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg single dose. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung cancer	Lung cancer cells		Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 1 mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung cancer	Lung cancer cells		Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Negative 5T4 expression (5T4-)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg Q4D 3. Click to Show/Hide
In Vivo Model	Gastric cancer CDX model
In Vitro Model	Gastric cancer	Gastric cancer cells		Homo sapiens
Experiment 9 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Negative 5T4 expression (5T4-)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg single dose. Click to Show/Hide
In Vivo Model	Gastric cancer CDX model
In Vitro Model	Gastric cancer	Gastric cancer cells		Homo sapiens
Experiment 10 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High 5T4 expression (5T4+++)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ubcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 10 mg/kg single dose.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells (5T4 overexpression)		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High 5T4 expression (5T4+++)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 6mg/kg Q4D 4.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells (5T4 overexpression)		CVCL_0062
Experiment 12 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High 5T4 expression (5T4+++)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg Q4D 4.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells (5T4 overexpression)		CVCL_0062
Experiment 13 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High 5T4 expression (5T4+++)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 1 mg/kg Q4D 4.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells (5T4 overexpression)		CVCL_0062
Experiment 14 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 10 mg/kg single dose. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 15 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 6mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 16 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 3 mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 17 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low 5T4 expression (5T4+)
Method Description	ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm³. The dose of ASN004 was 1 mg/kg Q4D 4. Click to Show/Hide
In Vivo Model	Cervical cancer CDX model
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037

Revealed Based on the Cell Line Data

Click To Hide/Show 32 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	High 5T4 expression (5T4+++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder squamous cell carcinoma	SCaBER cells		CVCL_3599
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	High 5T4 expression (5T4+++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	5637 cells		CVCL_0126
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 7 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105
Experiment 8 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 9 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 10 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 11 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.26 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 12 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.31 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728
Experiment 13 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.34 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 14 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.42 nM	High 5T4 expression (5T4+++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells (5T4 overexpression)		CVCL_0062
Experiment 15 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.42 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Prostate carcinoma	PC-3 cells		CVCL_0035
Experiment 16 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.44 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Gestational choriocarcinoma	JEG-3 cells		CVCL_0363
Experiment 17 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.56 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 18 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	Negative 5T4 expression (5T4-)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 19 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.62 nM	Negative 5T4 expression (5T4-)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 20 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.66 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	TCCSUP cells		CVCL_1738
Experiment 21 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.76 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Recurrent bladder carcinoma	HT-1197 cells		CVCL_1291
Experiment 22 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.78 nM	Negative 5T4 expression (5T4-)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	RT-4 cells		CVCL_0036
Experiment 23 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.93 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	T24 cells		CVCL_0554
Experiment 24 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.95 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 25 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.03 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Breast ductal carcinoma	HCC1937 cells		CVCL_0290
Experiment 26 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.05 nM	Low 5T4 expression (5T4+)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Lung large cell carcinoma	NCI-H1299 cells		CVCL_0060
Experiment 27 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.06 nM	High 5T4 expression (5T4+++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	HT-1376 cells		CVCL_1292
Experiment 28 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.34 nM	Negative 5T4 expression (5T4-)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Lung small cell carcinoma	DMS 114 cells		CVCL_1174
Experiment 29 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.53 nM	Negative 5T4 expression (5T4-)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	UM-UC-3 cells		CVCL_1783
Experiment 30 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.28 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Bladder carcinoma	J82 cells		CVCL_0359
Experiment 31 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.01 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 32 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.03 nM	Moderate 5T4 expression (5T4++)
Method Description	The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

References

Ref 1	Study of ASN004 in Patients With Advanced Solid Tumors
Ref 2	ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Mol Cancer Ther. 2021 Aug;20(8):1327-1337.

Antibody-drug Conjugate Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)